Sep 04, 2020 / 03:40PM GMT
Unidentified Analyst -
Our next presenting company is AzurRx BioPharma, a biopharmaceutical company engaged in the research and development of nonsystemic biologics for the treatment of patients with gastrointestinal disorders. Join us in welcoming...
James R. Sapirstein - AzurRx BioPharma, Inc. - CEO, President & Non-Independent Director
Good morning, everyone. This is James Sapirstein, the President and CEO of AzurRx. Thank you very much for attending our presentation today. And Azur is a company on Nasdaq. Just going to go through some of our disclaimers. As you know, we're a publicly traded company, so you'll be hearing some statements that may or may not be currently available. But for the most part, I will be presenting everything that's currently available.
So who is AzurRx? We've been around since 2014 and went public in 2016. We have the recombinant lipase for treatment of exocrine pancreatic insufficiency, a product called MS1819. At this juncture, we are targeting patients with cystic fibrosis and chronic pancreatitis. We're addressing a global
AzurRx BioPharma Inc at LD 500 Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers